Published Research
Sunstone powers trials to address complex mental health challenges and disorders while training therapists and optimizing the healing potential for patients.
01
Sunstone designs and delivers innovative clinical trials with leading psychedelic drug developers and medical bodies.
- Beckley Psytech
- COMPASS Pathways
- Cybin
- Lykos Therapeutics
- MindMed
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
02
We work with a broad range of psychedelics.
- Psilocybin
- MDMA
- LSD
- 5-MeO-DMT
- Methylone
- RE-104 (serotonergic antidepressant)
03
Across a wide array of clinical indications.
- Adjustment Disorder (AD)
- Demoralization in Patients with Cancer
- Palliative Care (End of Life)
- Generalized Anxiety Disorder (GAD)
- Major Depressive Disorder (MDD)
- Major Depressive Disorder in Patients with Cancer
- Post-Traumatic Stress Disorder (PTSD)
- Postpartum Depression
- Treatment-Resistant Depression (TRD)
04
In partnership with top-tier academic and medical institutions.
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic & Consciousness Research
- McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Sunstone Published Research
Explore our growing list of published research featured in medical journals and publications.
-
Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
Read More: Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
-
Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. “Adverse Events Should Not Be Surprising in Psychedelic Research.” Psychedelic Medicine, September 2024.
Read More: Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. “Adverse Events Should Not Be Surprising in Psychedelic Research.” Psychedelic Medicine, September 2024.
-
Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. “Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.” International Review of Psychiatry, May 2024.
Read More: Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. “Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.” International Review of Psychiatry, May 2024.
-
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
Read More: Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
-
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Read More: Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
-
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
Read More: Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” J Palliat Med, Aug. 2023.
-
Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
Read More: Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
-
Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
Read More: Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
-
Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
Read More: Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
-
Agrawal M., Thambi P., Shnayder S. “The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder” Journal of Clinical Oncology, June 2022.
Read More: Agrawal M., Thambi P., Shnayder S. “The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder” Journal of Clinical Oncology, June 2022.
-
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. “Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?” Journal of Psychopharmacology, Jan 2022.
Read More: Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. “Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?” Journal of Psychopharmacology, Jan 2022.